Jeffreys Henry LLP, the leading UK audit firm for AIM, ISDX and GXG listed companies, has recently advised Vialogy Plc on the reverse takeover and subsequent AIM re-admission of Premaitha Health Plc.

Premaitha Health, which employs next generation DNA analysis technology to develop, manufacture and sell molecular diagnostic products intended to have a major beneficial impact on human health, was valued at £20.7 million on the day of admission.

Adam Reynolds, Chairman of Vialogy Plc, commented:

“I have been delighted with the quality and efficiency of Jeffreys Henry who acted as Reporting Accountants on this complex AIM transaction involving the reverse takeover of Premaitha Healthcare by Vialogy Plc. I was very impressed with the structured advise given and the ability to conclude the acquisition in a very timely manner.”

With 32 listed clients, ranked one of the UK’s top 11 auditors by Total Stock Market clients, a team dedicated to working with listed companies, access to a global network and lower fees, Jeffreys Henry is a real alternative to the larger audit firms for companies already listed, or considering listing, on AIM, ISDX or GXG markets.